Anti-tubercular chemotherapy and drug induced hepatitis

HealthMED

Volumn 4, Issue 3, 2010, Pages 536-544

  Khan, Amer Hayat ^a   Sulaiman, Syed Azhar Syed ^a   Hassali, Mohamed Azmi ^a   Razzak Muttalif, A ^b  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b HOSPITAL PULAU PINANG   (Malaysia)

Author keywords

Anti tubercular chemotherapy; Drug induced hepatotoxicity; Hepatotoxicity; Risk factors; Tuberculosis

Indexed keywords

EID: 77957308088     PISSN: 18402291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. 1991. Bull World Health Organ 2001;79:71-75.
2. Parasarthy, Raghupati, Sharma RG, Janardanam B, Ramachandran P, Santha T, et al. Hepatic toxi-city in South Indian patient during treatment of TB with short course regimen containing INH, RMP and PZA. Tubercle 1986;67: 69-108.
3. Koponoff DE, Snider DE Jr, Caras GJ. INH-related hepatitis: a US-public health service co-operative surveillance study. Am Respir Dis 1978;117(6):991-1001.
4. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. INH-associated hepatitis; report of outbreak. Am rev Respir Dis 1972;106.
5. Timbrell JA, Park BK, Harland SJ. A study of the effects of RMP on INH metabolism in human volunteers. Hum Toxicol 1985;4:279-85.
6. Snider DE, Caras GJ. INH-associated hepatitis deaths: A review of available information. Am Rev Respir Dis 1992;145:494-7.
7. Omerod LP, Skinner C, Wales J. Hepatotoxicity of anti-TB drugs. Thorax 1996;51:111-3.
8. Türktaş H, Ünsal M, Tülek N, Örüç O. Hepatotoxicity of antituberculosis therapy (rifampicin, isonia-zid and pyrazinamide) or viral hepatitis. Tubercle Lung Dis 1994; 75:58-60.
9. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuber-culosis shortcourse chemotherapy trial 21: Effectiveness, toxicity and acceptability. The report of final results. Ann Intern Med 1990; 112:397-406.
10. British Thoracic Society and Tuberculosis Association. Short course chemotherapy in pulmonary tuberculosis. Lancet 1975;305:119-24.
11. Marzuki OA, Fauzi ARM, Ayoub S, Kamarul Imran M. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J 2008; 49 (9): 688.
12. Teleman MD, Chee CB, Earnest A, et al. Hepa-totoxicity of tuberculosis chemotherapy under a general program conditions in Singapore. Int J Tuberc Lung Dis 2002; 6:699-705.
13. Ministry of Health Malaysia. Annual report 2002, 2003.
14. Durand F, Bernuau J, Pessalre D et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculosis treatment including Isoniazid. Hepatology 1995;21:929-32.
15. Singh J, Arora A, Garg PK, Thakur VS, Pande N, Tandon RK. Anti-tuberculosis treatment-induced hepatotoxicity: role of predictive factors. Po-stgrad. Med. J. 1995;71:359-62.
16. Schaberg T, Rebhan K, Lode H. Risk factors for side effects of Isoniazid, rifampin and Pyrazina-mide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J. 1996;9:2026-30.
17. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first line anti-tuberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Carc Med. 2003;167:1472-7.
18. Monitoring and management of antituberculosis drug induced hepatotoxicity. Subhash Agal, Rajiv Baijal, Snehanshu Pramanik, Nikhil Patel, Gupte, Praful Kamani and Deepak Amarapurkar. Journal of Gastroenterology and Hepatology. 2005; 20:1745-1752
19. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf. 1996;15: 394-405.
20. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunological risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-9.
21. Mahashur AA, Prabhudesai PP. Hepatitis and antitubercular therapy. J Assoc Physicians India 1991;39:595-6
22. Hussain Z, Kar P, Husain SA. Anti Tuberculosis Induced Hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003;41(11):1226-1232.
23. Van der Kooi, J. J. Mottet, and C. Regamey. 1994. Isoniazid is not always the cause of hepatitis during the treatment of tuberculosis (letter). Clin. Infect. Dis. 19:987-988.
24. Bailey, W. C., S. L. Taylor, H. E. Dascomb, H. B. Greenberg, and M. M. Ziskind. 1973. Disturbed hepatic function during isoniazid chemoprop-hylaxis. Am. Rev. Respir. Dis.107:523-529.
25. Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi B, Salkeen S. Hepatotoxicity with antituberculosis drugs: the risk factors. Pak J Med Sci. 2007;23:33-38.
26. Monitoring and management of antituberculosis drug induced hepatotoxicity. Subhash Agal, Rajiv Baijal, Snehanshu Pramanik, Nikhil Patel, Parijat Gupte, Praful Kamani and Deepak Amarapurkar. Journal of Gastroenterology and Hepatology. 2005; 20:1745-1752
27. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf. 1996;15: 394-405.
28. Mitchell I, Wendon J, Fitt S, Williams R. Antituberculous therapy and acute liver failure. Lancet 1995; 345: 555-556.
29. Villor AF, Sopena B, Villor JF. The influence of risk factors on the severity of antituberculosis drug induced hepatotoxicity. Int J Tuberc Lung Dis 2004;8:1499-1505.
30. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005;26:462-464.
31. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. Can Med Assoc J 2002;167:131-136.
32. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003;37:924-930.
33. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the aryla-mine N-acetyltransferase 2 polymorphism valida-ted by phenotyping with isoniazid. J Med Genet 1997;34:758-760.
34. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005;127:1304-1311.
35. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996;77:37-42.
36. Hoda A. Makhlouf, Ahmed H, Ehab F, Madiha E, Hebat Alla G. R. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol Int. 2008; 2:353-360.
37. Anti-tuberculosis drugs and liver toxicity, (letter to editor) Eur Respir J, 1996, 9, 389-390.
38. Mitchell I, Wendon J, Fitt S, Williams R. Antituberculous therapy and acute liver failure. Lancet 1995; 345: 555-556.
39. Mehta S. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther. 1990;15:159-165.
40. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996;51:132-136.